04/02/2026
A new clinical research study is now underway for individuals living with BEST1-associated retinal disease. The BIRD-1 study is evaluating an investigational gene therapy for people diagnosed with BVMD or ARB who have a confirmed BEST1 mutation. Research like this helps move the field forward and brings hope to families affected by inherited retinal diseases. Learn more about eligibility and study details at https://bit.ly/4sOdOPg or email patientsupport@opusgtx.com.
This post is sponsored by Opus Genetics.
Image Description: Dark blue background with the Foundation Fighting Blindness logo at the top, with text below in green that says "Partner News." Below that is the text "Learn about BIRD-1: Gene Therapy Study for BEST1 Disease," followed by the Opus Genetics logo.